Slide 1: Investor Presentation February 6, 2025
Investor Presentation February 6, 2025
Slide 2: Forward-looking statements
This presentation contains “forward - looking statements” within the meaning of federal securities laws. These forward - looking sta tements include statements with respect to 2025 guidance, strategic and growth opportunities, other expectations and other non - historical information. Without limiti
Slide 3: Our Guiding Principles
© 2025 Omnicell, Inc. 3 Investor Presentation – February 6, 2025 Our Guiding Principles Our Purpose To be the healthcare providers’ most trusted partner to enable the Autonomous Pharmacy transformation Our Guiding Principles represent what we stand for as a company, guiding us in every aspect of how
Slide 4: Omnicell Investment Highlights
© 2025 Omnicell, Inc. 4 Omnicell Investment Highlights Investor Presentation – February 6, 2025 A recognized leader in medication management with a 30 - year track record and an installed base that includes more than one - half of the top 300 U.S. health systems * Investing in SaaS and Expert Servic
Slide 5: Omnicell's Growth Strategy
© 2025 Omnicell, Inc. 5 Omnicell’s Growth Strategy is to: Investor Presentation – February 6, 2025 CONNECT the health network GROW where care is being delivered DISRUPT Pharmacy care with innovation
Slide 6: Our Strategy
© 2025 Omnicell, Inc. Our Strategy Investor Presentation – February 6, 2025 HEALTH SYSTEM OUTPATIENT Central Pharmacy/ Centralized Service Center IV Room Points of Care Specialty Pharmacy Ambulatory Care Omnicell is transforming pharmacy care through outcomes - centric solutions combining robotics a
Slide 7: The Autonomous Pharmacy Industry-Defined Vision
The Autonomous Pharmacy Investor Presentation – February 6, 2025 Industry - Defined Vision Replace manual, error - prone activities with automated processes that are designed to be safer and more efficient. o Zero medication errors o Zero medication waste o Zero human touches until delivery to patie
Slide 8: Outcomes Delivered
© 2025 Omnicell, Inc. 8 Investor Presentation – February 6, 2025 OUTCOME DELIVERED 25,000 Errors Annually in Hospitals 1 $4.5B Net loss for a major healthcare provider in FY ’22 2 $39B Spent in compliance administration 3 623 Hospitals expect critical staffing shortages 4 75% Pharmacists’ tasks are
Slide 9: Revenue Growth Drivers
© 2025 Omnicell, Inc. 9 Revenue Growth Drivers Investor Presentation – February 6, 2025 Deep Customer Relationships and Robust Backlog o Strong position with more than one - half of the top 300 U.S. health systems o Robust backlog of $1.201 billion as of 12/31/2024 1 Multiple Growth Drivers o Expans
Slide 10: SaaS and Expert Services Recurring Revenue Growth
© 2025 Omnicell, Inc. 10 SaaS and Expert Services* Recurring Revenue Growth Investor Presentation – February 6, 2025 SaaS and Expert Services Potential Revenue Opportunity o Leveraging established channels and strong customer relationships o Demand driven by increasing provider digitization and need
Slide 11: Why We Believe Omnicell is Positioned to Win
© 2025 Omnicell, Inc. 11 Why We Believe Omnicell is Positioned to Win Investor Presentation – February 6, 2025 Omnicell has the right solutions and the right business model to solve the medication management problem that the healthcare system is facing Omnicell has a proven track record of innovatio
Slide 12: Product Overview
Product Overview
Slide 13: Points of Care
© 2025 Omnicell, Inc. 13 Points of Care XT Automated Supply Dispensing Cabinets XT Anesthesia Workstation Inventory Optimization Service XT Automated Dispensing Cabinet Investor Presentation – February 6, 2025 As the final step in the pharmaceutical administration process, the bedside exchange of me
Slide 14: Central Pharmacy
© 2025 Omnicell, Inc. 14 Central Pharmacy Pharmacy Carousel Inventory Optimization Service Central Pharmacy Dispensing Service Investor Presentation – February 6, 2025 Central pharmacy is the medication dispensing hub of most hospitals. Roadblocks that surface here have the potential to impact patie
Slide 15: IV Room
© 2025 Omnicell, Inc. 15 IV Room IVX Workflow IV Compounding Service Investor Presentation – February 6, 2025 Accuracy and sterility in IV compounding are paramount to patient safety, but an overreliance on 503B outsourcing and manual in - house systems often creates unnecessary risk and expense. Om
Slide 16: Specialty Pharmacy
© 2025 Omnicell, Inc. 16 Specialty Pharmacy Omnicell 340B Specialty Pharmacy Services Investor Presentation – February 6, 2025 As medical innovations create new, more complex drugs, many pharmacies need specialized tools and expertise to help manage the patient’s treatment journey. Opening or optimi
Slide 17: Ambulatory Care
© 2025 Omnicell, Inc. 17 Ambulatory Care EnlivenHealth® Investor Presentation – February 6, 2025 Optimizing a patient’s medication journey often means extending care beyond the inpatient setting and enhancing the processes of retail and community pharmacies. Through EnlivenHealth®, Omnicell provides
Slide 18: Medication Adherence
© 2025 Omnicell, Inc. 18 Medication Adherence Packaging Equipment Automation Packaging and Labeling Solutions Investor Presentation – February 6, 2025 Through industry - leading packaging and automation solutions, Omnicell Medication Adherence helps to empower pharmacies to work more efficiently as
Slide 19: Omnicell's Suite of SaaS and Expert Services
© 2025 Omnicell, Inc. 19 Omnicell’s Suite of SaaS and Expert Services* Investor Presentation – February 6, 2025 IV Compounding Central Pharmacy/ Centralized Services Center Points of Care Inventory Optimization Ambulatory Pharmacy Care Specialty Pharmacy Varying combinations of robotics and smart de
Slide 20: Omnicell 2024 Innovation
© 2025 Omnicell, Inc. 20 Omnicell 2024 Innovation Investor Presentation – February 6, 2025 XT Amplify April 2024 Innovative suite of solutions designed to enhance pharmacy and nursing efficiency, reduce medication errors and waste, and maximize the value of the XT Automated Dispensing System Central
Slide 21: XT Amplify
© 2025 Omnicell, Inc. 21 XT Amplify Investor Presentation – February 6, 2025 XTExtend MedChill SupplyXpert ServerScale CarePlus Innovative solutions designed to maximize the value of XT technology
Slide 22: Central Med Automation Service
© 2025 Omnicell, Inc. 22 Central Med Automation Service Investor Presentation – February 6, 2025 Robotics and Smart Devices Software Expert Services Transforming Pharmacy Care A powerful solution designed to ensure your pharmacy operations excel today and evolve seamlessly into the future.
Slide 23: OmniSphere
© 2025 Omnicell, Inc. 23 OmniSphere Investor Presentation – February 6, 2025 o State - of - the - art security through a scalable infrastructure and platform with certified cyber and data security o Improved productivity with one point of access for all cloud - connected Omnicell automation o Enterp
Slide 24: Fourth Quarter and Full Year 2024 Financial Highlights
Fourth Quarter and Full Year 2024 Financial Highlights
Slide 25: Financial Snapshot
© 2025 Omnicell, Inc. 25 Financial Snapshot Investor Presentation – February 6, 2025 See Appendix for a reconciliation of Q4 – 2024 Non - GAAP Gross Margin, Q4 – 2024 Non - GAAP Operating Expenses, Q4 – 2024 Non - GAAP EBITDA and Q4 - 2024 Non - GAAP Diluted Earnings Per Share to their most directly
Slide 26: New Metrics for 2025
© 2025 Omnicell, Inc. 26 New Metrics for 2025 Investor Presentation – February 6, 2025 o Our previous Bookings metric included Connected Devices and Software Licenses, SaaS and Expert Service* and Consumables. o For 2025, our new Product Bookings metric consists of Connected Devices and Software Lic
Slide 27: 2024 Product Bookings and ARR Look Back
© 2025 Omnicell, Inc. 27 2024 Product Bookings and ARR Look Back Investor Presentation – February 6, 2025 o Our previous Bookings metric included Connected Devices and Software Licenses, SaaS and Expert Services* and Consumables. For 2024, Bookings using the previous Bookings metric were $923M o For
Slide 28: 2025 Guidance
© 2025 Omnicell, Inc. 28 2025 Guidance Investor Presentation – February 6, 2025 Long - Term Value Creation Opportunities o Leadership position in the digital transformation of healthcare o Emerging and scaling of SaaS & Expert Services offerings o Platform adoption, expansion, market share gains, an
Slide 29: A Better Way: ESG in Action
© 2025 Omnicell, Inc. A Better Way: ESG in Action Investor Presentation – February 6, 2025 Environment 89% of Board is independent 56% of Board are women or racially or ethnically diverse 2023 ESG Report Published fourth annual ESG Report in April 2024 o Decreased Scope 1 and 2 emissions in 2023 by
Slide 30: Appendix
Appendix
Slide 31: (a) For the year ended December 31, 2023, impairment charges of other assets were
© 2025 Omnicell, Inc. 31 (a) For the year ended December 31, 2023, impairment charges of other assets were approximately $0.6 million related to property and equipment in connection with restructuring activities for optimization of certain leased facilities.
Slide 32: (a) For the year ended December 31, 2023, impairment charges of other assets were
© 2025 Omnicell, Inc. 32 (a) For the year ended December 31, 2023, impairment charges of other assets were approximately $0.6 million related to property and equipment in connection with restructuring activities for optimization of certain leased facilities. (b) Tax effects calculated for all adjust
Slide 33: (a) For the year ended December 31, 2023, impairment charges of other assets were
© 2025 Omnicell, Inc. 33 (a) For the year ended December 31, 2023, impairment charges of other assets were approximately $0.6 million related to property and equipment in connection with restructuring activities for optimization of certain leased facilities. (b) Tax effects calculated for all adjust
Slide 34: (a) For the year ended December 31, 2023, impairment charges of other assets were
© 2025 Omnicell, Inc. 34 (a) For the year ended December 31, 2023, impairment charges of other assets were approximately $0.6 million related to property and equipment in connection with restructuring activities for optimization of certain leased facilities. (c) Defined as earnings before interest i
Slide 35: Glossary of Terms
© 2025 Omnicell, Inc. 35 Glossary of Terms Investor Presentation – February 6, 2025 Bookings (Historical Metric): We utilize bookings as an indicator of the success of our business. During 2024, we defined bookings generally as: ( i ) the value of non - cancelable contracts for our connected devices
Slide 36: Glossary of Terms Continued
© 2025 Omnicell, Inc. 36 Glossary of Terms Continued Investor Presentation – February 6, 2025 Product Bookings: (New Metric for 2025): We define product bookings generally as the value of non - cancelable contracts for our connected devices and software licenses. We typically exclude freight revenue
Slide 37: Slide 37